PQA Pharmacy Performance Measures in Development
Pharmacy performance measures evaluate quality of pharmacies and assess pharmacist-provided care and pharmacy-based services. Pharmacy performance measures provide pharmacists the opportunity to demonstrate their contributions toward high-quality, patient-centered care.
PQA is developing a set of standard pharmacy performance measures that would be appropriate for pharmacy accountability, once assessed against standard measure criteria and endorsed by PQA membership.
Overview of Current Measure Development Work
PQA's Pharmacy Measure Development Action Plan guides the organization's continued work to build out a pharmacy measure set suitable for payer-pharmacy arrangements. It outlines next steps for developing measure concepts that were prioritized based on their feasibility and usability. PQA launched three Technical Expert Panels (TEPs) in 2020 and 2021 to develop prioritized pharmacy measure concepts. Each is listed below, along with their status of development:
- Hemoglobin A1c Reporting (Pharmacy) and Blood Pressure Reporting (Pharmacy)
- PQA aims to complete specification of these two measure concepts in early 2022 and will be seeking testing partners* at that time
- Continuous Antidepressant Medication Therapy (Pharmacy) (CAT-PH)
- Moving into the testing phase; PQA currently is seeking testing partners*
- Proportion of Days Covered Composite: Renin Angiotensin System Antagonists, Statins, and Diabetes medications (Pharmacy) (PDC-CMP-PH)
*Contact PQA's Performance Measurement Team at [email protected] to learn more about testing opportunities.
TEPs to develop additional prioritized concepts will be launched in 2022 and beyond, to continue to build out PQA's set of standardized pharmacy measures.
Resources and Updates
- PQA and CPF Lead National Initiative to Prioritize Pharmacy Measure Concepts (September 9, 2021)
- PQA and CPF Bring Health Care Leaders Together to Prioritize Pharmacy Quality Measures for Development (February 4, 2021)
- PQA Update on Development of Pharmacy Measures: Pharmacy Measure Development Action Plan (November 10, 2020)
- Memo for the PQA Public Comment Period on PQA's Draft Pharmacy Measure Development Action Plan (Comment period occurred August 6-28, 2020)
- PQA Stakeholder Advisory Meeting on the Draft Pharmacy Measure Development Action Plan (Recording) (August 6, 2020)
- PQA Update on Development of Pharmacy Measures: The Pharmacy Measure Development Action Plan (July 21, 2020)
- PQA Endorses Three New Pharmacy Performance Measures (February 6, 2020)
- Summary description of three new pharmacy performance measures recommended for endorsement by PQA (includes key points, specifications for each measure, and a description of PQA's Measure Development Process) (December 18, 2019)
- PQA Update on Development of Pharmacy Measures (October 15, 2019)
- PQA Update on Development of Pharmacy Measures (September 26, 2019)
- Memo for the PQA Public Comment Period on PQA’s Proposed Standard Measure Set for Pharmacy Accountability in Value-Based Models (Comment period occurred August 22-September 6, 2019)
- PQA All-Member Webinar: Building Consensus on Measures for Plan-Pharmacy Agreements (Recording) (August 22, 2019)
- PQA Summary from Building Consensus on Measures for Plan-Pharmacy Agreements: A Workshop to Develop a Roadmap for Standard Quality Measures (July 31- August 1, 2019)
Questions about PQA’s pharmacy measure development should be directed to PQA’s Performance Measurement Team at [email protected].
|
